identical immune response received dose added ultimately fda decide authorize change dosing additionally data half doses phase ii clinical trial not sufficient evidence half doses prevent disease crotty notes ultimately risks altering data backed vaccine dosing strategies outweigh benefits discussions changing dosing regimen data support create doubt skepticism process lead increased vaccine hesitancy rasmussen says crotty agrees emergency situations think reasonable dialog says end think important proven scientific american tanya lewis senior editor covers health medicine credit nick higgins january 7 2021 claudia wallis january 4 2021 charles schmidt january 8 2021 ewen callaway nature magazine january 1 2021 akiko